Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
All right. Very good. It's my pleasure to be hosting this panel with Brett Monia, CEO of Ionis. I'm sure most folks know the Ionis story quite well. But maybe I can just have Brett give a quick 2- to 3-minute intro the scope of the pipeline, what's kind of key and that's upcoming, and then we can get into Q&A. So thank you.
It sounds good. Pleasure to be here, Paul. Thank you. So Ionis is a genetic medicines company traditionally has been focused on the antisense platform. Today, we're more diversified in our technology. Certainly, [antisense is a key to our] technology with 9 drugs in Phase III development for 11 indications.
But we've also expanded our capabilities into RNAi and even gene editing now. It's been a very exciting year for the pipeline with several positive readouts and preparing for upcoming commercial launches next year
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |